Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical HSCT for Sickle Cell and Thalassemia
NCT02165007Phase 1Completed
- Sponsor
- Catherine Bollard
- Start
- Jan 2015
- Primary completion
- Jan 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD34-selected peripheral blood stem cells in sickle cell disease (SCD) and thalassemia, sponsored by Catherine Bollard. Primary endpoint: Incidence of transplant related adverse outcomes at 60 days. Started Jan 2015; status: completed.
02
Drugs
CD34-selected peripheral blood stem cells
03
Conditions
sickle cell disease (SCD)thalassemia
Beyond the preview
Go deeper on NCT02165007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02165007.